Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
7.535USD
+0.175+2.38%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
214.17MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Arcturus Therapeutics Holdings Inc is 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. The average price target is 21.50, with a high of 68.00 and a low of 9.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
23.000
Target Price
+213.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Arcturus Therapeutics Holdings Inc
ARCT
12
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Arcturus Therapeutics Holdings Inc's expected revenue for the next quarter?
Arcturus Therapeutics Holdings Inc's expected revenue is 3.41M.
What is Arcturus Therapeutics Holdings Inc's price target?
Analysts forecast that Arcturus Therapeutics Holdings Inc's price target is USD 21.50, with the highest forecast at USD 68.00 and the lowest forecast at USD 9.00.
How have Arcturus Therapeutics Holdings IncARCT's recent earnings per share performed?
The market expectation was USD -0.95, while Arcturus Therapeutics Holdings IncARCT's earnings per share (EPS) for the previous quarter was USD -1.03. EPS for the next quarter is expected at USD -1.03.
What is the analyst rating for Arcturus Therapeutics Holdings Inc?
Based on the ratings of Arcturus Therapeutics Holdings Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
